ACS Nano · 2010 · 412 citations · 40 references
Natural SciencesBioengineeringOncologyNanobiotechnologyNanomaterialsNanotechnologyCancer NanomedicineInorganic NanoparticlesNanomedicineQuantum DotsQuantum Dots In BiologySemiconductor NanomaterialsBioconjugationMicelle EncapsulationMulticolor ImagingNanoparticle BioconjugationNanoparticle Imaging AgentsSize-dependent Optical PropertiesTargeted BioimagingTumor Vasculature Targeting
Quantum dots have size‑dependent optical properties that enable in‑vivo targeted fluorescence imaging, traceable delivery, and therapy, but group II‑VI QDs contain toxic heavy metals that limit their use. Replacing toxic group II‑VI QDs with biocompatible silicon QDs is desirable. We overcome dispersibility and functionalization challenges by synthesizing Si QDs, surface‑functionalizing them, encapsulating in PEGylated micelles, and bioconjugating to produce bright, targeted nanospheres with stable luminescence and >40 h tumor accumulation in vivo. We demonstrate that properly encapsulated biocompatible Si QDs enable tumor vasculature targeting, sentinel lymph node mapping, and multicolor NIR imaging in live mice, and anticipate that they will facilitate more sophisticated in‑vivo models by reducing toxicity while preserving QD imaging advantages.
Quantum dots (QDs) have size-dependent optical properties that make them uniquely advantageous for in vivo targeted fluorescence imaging, traceable delivery, and therapy. The use of group II−VI (e.g., CdSe) QDs for these applications is advancing rapidly. However, group II−VI QDs contain toxic heavy metals that limit their in vivo applications. Thus, replacing these with QDs of a biocompatible semiconductor, such as silicon (Si), is desirable. Here, we demonstrate that properly encapsulated biocompatible Si QDs can be used in multiple cancer-related in vivo applications, including tumor vasculature targeting, sentinel lymph node mapping, and multicolor NIR imaging in live mice. This work overcomes dispersibility and functionalization challenges to in vivo imaging with Si QDs through a unique nanoparticle synthesis, surface functionalization, PEGylated micelle encapsulation, and bioconjugation process that produces bright, targeted nanospheres with stable luminescence and long (>40 h) tumor accumulation time in vivo. Upon the basis of this demonstration, we anticipate that Si QDs can play an important role in more sophisticated in vivo models, by alleviating QD toxicity concerns while maintaining the key advantages of QD-based imaging methods.
40
In vivo cancer targeting and imaging with semiconductor quantum dots
Xiaohu Gao, Yuanyuan Cui, Richard M. Levenson et al. · Nature Biotechnology · 2004 · 4.7K citations
Probing the Cytotoxicity of Semiconductor Quantum Dots
Austin M. Derfus, Warren C. W. Chan, Sangeeta N. Bhatia · Nano Letters · 2003 · 3.4K citations · Full text
In Vivo Imaging of Quantum Dots Encapsulated in Phospholipid Micelles
Benoît Dubertret, Paris A. Skourides, David J. Norris et al. · Science · 2002 · 3K citations
Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping
Sungjee Kim, Yong Taik Lim, Edward G. Soltesz et al. · Nature Biotechnology · 2003 · 2.1K citations
Biodegradable luminescent porous silicon nanoparticles for in vivo applications
Ji‐Ho Park, Luo Gu, Geoffrey von Maltzahn et al. · Nature Materials · 2009 · 1.9K citations · Full text
Natural Sciences, Biomedical Engineering, Materials Science +14